C&R Research

씨엔알리서치 · 359090

Industrials Commercial Services · KOSDAQ

Small-cap

Market cap US$21.3M (₩29.4B)

Overview

C&R Research manages clinical trials on behalf of pharmaceutical companies and biotech ventures, handling everything from study design and protocol development through statistical analysis and regulatory reporting, so drug developers can outsource the research process entirely.

Listed on KOSDAQ, Korea's tech and small-cap board, it serves domestic pharmaceutical firms and biotech startups as its primary clients. Its business is knowledge-intensive and requires no physical facilities or raw materials, with revenue recognised progressively over the life of each contracted project.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$47.1M
▲ +8.9% YoY
Operating profit · FY2025
US$1M
▼ −61.9% YoY
Net income · FY2025
US$740K
▼ −69.6% YoY

Revenue

  • FY2023US$39.9M
  • FY2024US$43.3M
  • FY2025US$47.1M

Operating profit

  • FY2023US$4.5M
  • FY2024US$2.6M
  • FY2025US$1M

Net income

  • FY2023US$4M
  • FY2024US$2.4M
  • FY2025US$740K

Key ratios (FY2025)

ROE
2.1%
Debt/Eq
76.9%
Op. margin
2.1%
Net margin
1.6%
Rev. YoY
▲ +8.9%

Why it matters

The company operates a subsidiary, Trial Informatics, to which it has transferred certain clinical-trial IT platform assets, running two distinct business lines, clinical trial services and clinical IT solutions, in parallel.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.